Axogen, Inc. to Participate in the 24th Annual Morgan Stanley Global Healthcare Conference
Axogen (NASDAQ: AXGN) announced that its management team will participate in the 24th Annual Morgan Stanley Global Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Axogen (NASDAQ: AXGN) announced that its management team will participate in the 24th Annual Morgan Stanley Global Healthcare Conference. According to Axogen, management will be available for one-on-one investor meetings at the event on Tuesday, September 15, 2026.
Details
News Market Reaction – AXGN
On Sep 1, the day this news came out, AXGN closed 1.73% below the previous close. Our momentum scanner recorded 2 alerts in the available session data.
Data tracked by StockTitan Argus for the Sep 1 session.
Key Figures
- Conference edition
- 24th Annual
- Morgan Stanley Global Healthcare Conference
- Meeting date
- September 15, 2026
- One-on-one investor meetings
Historical Context
-
Strategic investment announcement; 24-hour reaction was +0.53%.
-
Revenue growth and raised guidance; 24-hour reaction was +0.53%.
-
Scheduled Q2 results release; 24-hour reaction was -0.13%.
-
Healthcare conference participation; 24-hour reaction was +3.42%.
-
Raised revenue guidance and completed offering; reaction was +6.6%.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ALACHUA, Fla. and TAMPA, Fla., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management will be available for one-on-one investor meetings at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026.
About Axogen
Axogen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about providing the opportunity to restore nerve function and quality of life for patients with peripheral nerve injuries by providing innovative, clinically proven and economically effective repair solutions for surgeons and healthcare providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve or the inability to properly reconnect peripheral nerves can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.
Axogen’s product portfolio includes Avance® (acellular nerve allograft-arwx), Avance® Nerve Graft, Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, and Avive+ Soft Tissue Matrix™.
Contact:
Axogen, Inc.
InvestorRelations@axogeninc.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.